{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to small number of events.","groupId":"OG000","lowerLimit":"14.1","upperLimit":"NA","value":"52.3"},{"comment":"Not estimable due to small number of events.","groupId":"OG001","lowerLimit":"1.5","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"OS is defined as the time from the date of the first dose of study treatment to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with an increased risk of tumor lysis syndrome (TLS) enrolled into the open-label Safety Run-in Period received concurrent ibrutinib at 560 mg once daily and venetoclax starting at 20 mg, and gradually ramped up to a target dose of 400 mg once daily over a 5-week period.","id":"OG000","title":"Safety Run-in: Increased TLS Risk at Baseline"},{"description":"Participants with an low risk of TLS enrolled into the open-label Safety Run-in Period received concurrent ibrutinib at 560 mg once daily and venetoclax starting at 20 mg, and gradually ramped up to a target dose of 400 mg once daily over a 5-week period.","id":"OG001","title":"Safety Run-in: Low TLS Risk at Baseline"}],"paramType":"MEDIAN","populationDescription":"All Enrolled Safety Run-in participants","reportingStatus":"POSTED","timeFrame":"For an overall median time on study of 74.78 months","title":"Overall Survival (OS) (Safety Run-in)","type":"SECONDARY","unitOfMeasure":"months"}